CNS drug developers have to focus on physical safety and efficacy first, especially when developing products for rare disorders or diagnoses that are often unresponsive to other therapies. Although these products rarely have notable CNS mediated side effects, they fall under the FDA's requirement for an abuse potential assessment because they cross the blood-brain barrier.
Read MoreKlaus D. Mendla, Head of Global Business Development and Licensing CNS at Boehringer Ingelheim, will give a featured presentation on "Sincerely, Yours - Partnering with Boehringer Ingelheim in the CNS Space" at the 4th CNS Partnering and Deal-m
Read More